[Biomarker docetaxel-based chemotherapy].

about

New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.

P2860

Q38994718-11D30C30-C0C3-4F9A-AAAF-E5DDC2816E8D

P2860

[Biomarker docetaxel-based chemotherapy].

Item

http://www.wikidata.org/entity/Q46262484

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

[Biomarker docetaxel-based chemotherapy].

@en

[Biomarker docetaxel-based chemotherapy].

@nl

type

Item

label

[Biomarker docetaxel-based chemotherapy].

@en

[Biomarker docetaxel-based chemotherapy].

@nl

prefLabel

[Biomarker docetaxel-based chemotherapy].

@en

[Biomarker docetaxel-based chemotherapy].

@nl

P1476

[Biomarker docetaxel-based chemotherapy].

@en

P2093

A Heidenreich

http://www.w3.org/2001/XMLSchema#string

D Pfister

http://www.w3.org/2001/XMLSchema#string

D Porres

http://www.w3.org/2001/XMLSchema#string

P2860

Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

P304

1261-1264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00120-013-3318-Y

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23975220

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

[Biomarker docetaxel-based chemotherapy].

about

P2860

P2860

[Biomarker docetaxel-based chemotherapy].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921